Measuring Parkinson's Disease With Tear Fluid
| Status: | Recruiting |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 35 - Any |
| Updated: | 8/12/2018 |
| Start Date: | January 2017 |
| End Date: | January 2019 |
| Contact: | Danielle Feigenbaum, MD |
| Email: | danielle.feigenbaum@med.usc.edu |
| Phone: | 3234425710 |
Identification of Tear Biomarkers for Parkinson's Disease Patients
The purpose of this study is to assess whether tear secretion in patients with Parkinson's
disease will be altered to exhibit a characteristic or diagnostic biomarker profile, that
will be reflected in changes in the protein composition of tear fluid, which can be measured
relatively easily, cost-effectively, and non-invasively. Tear fluid samples will be collected
from Parkinson's patients, and through biochemical assays, the profile of proteins in tears
will be characterized and compared to that from control subjects. The profiles will be
analyzed with respect to any differences between Parkinson's patients and control subjects.
If differences appear, the levels of these potential biomarkers in Parkinson's patients will
be compared to the severity of their disease.
disease will be altered to exhibit a characteristic or diagnostic biomarker profile, that
will be reflected in changes in the protein composition of tear fluid, which can be measured
relatively easily, cost-effectively, and non-invasively. Tear fluid samples will be collected
from Parkinson's patients, and through biochemical assays, the profile of proteins in tears
will be characterized and compared to that from control subjects. The profiles will be
analyzed with respect to any differences between Parkinson's patients and control subjects.
If differences appear, the levels of these potential biomarkers in Parkinson's patients will
be compared to the severity of their disease.
Inclusion Criteria:
- established Parkinson's Disease for at least 6 months
- Healthy controls without neurological illness
Exclusion Criteria:
- currently taking anti-cholinergic medication
- dementia
- have an exposure to neuroleptic medications other than Quetiapine or Clozapine in the
6 months prior to screening
- have an active eye infection or have had eye surgery within 3 months prior to
screening
- control subjects will be excluded if they have a history of neurological disease
- PD subjects will be excluded if they have an atypical Parkinsonian syndrome
We found this trial at
1
site
University of Southern California The University of Southern California is one of the world’s leading...
Click here to add this to my saved trials
